MOdification of VIsual Outcomes After Optic Neuritis in CIS or MS by Gilenya (MOVING Study)

NCT01647880 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

TERMINATED

Status

15

Enrollment

OTHER

Sponsor class

Stopped delayed recruitment

Conditions

Multiple Sclerosis

Interventions

DRUG: Verum arm receiving Gilenya®
DRUG: Active Comparator receiving Extavia®

Sponsor

Charite University, Berlin, Germany

Collaborators

[object Object]